Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Orion Infusions's 10-Year ROIIC % for the quarter that ended in Jun. 2025 was 2.56%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Orion Infusions's 10-Year ROIIC % or its related term are showing as below:
DHA:ORIONINFU's 10-Year ROIIC % is ranked worse than 55.36% of 858
companies
in the Drug Manufacturers industry
Industry Median: 4.255
vs DHA:ORIONINFU: 2.56
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Orion Infusions 10-Year ROIIC % Related Terms
Orion Infusions 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Orion Infusions's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONINFU vs ZTS, UTHR, VTRS: 10-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions 10-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Orion Infusions's 10-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Orion Infusions (DHA:ORIONINFU) has a 10-Year ROIIC % of 2.56 as of Jun. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Orion Infusions and its competitors. According to the industry distribution chart, Orion Infusions ranks #475 out of 858 companies in the Drug Manufacturers industry, placing it in the top 55.4%.
Is Orion Infusions' 10-Year ROIIC % too high?
Orion Infusions' current 10-Year ROIIC % is 2.56. The Drug Manufacturers industry median 10-Year ROIIC % is 4.26. Orion Infusions' value of 2.56 is 39.8% below this industry median. Based on the distribution chart, Orion Infusions ranks #475 out of 858 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orion Infusions has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' 10-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #475 out of 858 companies for 10-Year ROIIC %. This places Orion Infusions in the lower half of its industry. The industry median 10-Year ROIIC % is 4.26. Orion Infusions' value of 2.56 is 39.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Drug Manufacturers company?
The median 10-Year ROIIC % among Drug Manufacturers companies is 4.26, based on 858 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Infusions's current 10-Year ROIIC % of 2.56 is 39.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Orion Infusions and its competitors. For the Drug Manufacturers industry, the median 10-Year ROIIC % is 4.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current 10-Year ROIIC % is 2.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT315.25, compared to a current price of BDT283.10 — trading 10.2% below its estimated fair value. The current 10-Year ROIIC % is 2.56 and 39.8% below the Drug Manufacturers industry median of 4.26. Orion Infusions' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current 10-Year ROIIC % is 2.56 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT283.10 is trading 10.2% below its estimated GF Value™ of BDT315.25.
GuruFocus considers Orion Infusions to be Modestly Undervalued.
Key valuation signals for DHA:ORIONINFU:
10-Year ROIIC %: 2.56
GF Value™: BDT315.25 vs. price of BDT283.10 (10.2% below fair value)
Industry Position: 39.8% below the Drug Manufacturers median (#475 of 858)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
80GF Score
Get the complete analysis for DHA:ORIONINFU
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
